A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Inclusion Criteria

• Treatment-naïve participants with Ann Arbor Stage III or IV HL.
• Histologically confirmed classical Hodgkin Lymphoma (HL) according to the current World Health Organization (WHO) classification.
• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (<=) 2.
• Bidimensional measurable disease as documented by radiographic technique per the International Working Group Revised Criteria for Response Assessment for Malignant Lymphoma.

Exclusion Criteria

• Nodular lymphocyte predominant Hodgkin lymphoma.
• Cerebral/meningeal disease, including signs and symptoms of progressive multifocalleukoencephalopathy (PML).
• Sensory or motor peripheral neuropathy.
• Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy within 12 weeks of first study drug dose.
• Known human immunodeficiency virus (HIV) positive.
• Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection. Please note that there are additional exclusion criteria. The study center will determine if you meet all of the criteria.